medigraphic.com
ISSN 0138-7103 (Print)

2021, Number 2

<< Back Next >>

Revista del Hospital Psiquiátrico de La Habana 2021; 18 (2)

Neuroplastics effects of depression in Alzheimer´s disease

Prendes-Rivero N, López-González B, Robinson-Agramonte MÁ, Verde-Corvo L, Mesa-Hernández NB

Language: Spanish
References: 28
Page:
PDF size: 393.42 Kb.


ABSTRACT

Introduction: The roads signaling of the brain-derived neurotrophic factor is affect in Alzheimer´s disease and depression.
Objective: To identify the possible association between the serum brain-derived neurotrophic factor levels and the cognitive function in patients with Alzheimer’s disease and depression.
Materials and methods: A study of cases in 51 aged subjects was carried out, they were distributed into three groups: 1) 21 Alzheimer´s disease patients, 2) 14 Alzheimer´s disease patients with depression and 3) 16 healthy controls. Were applied the geriatric depression scale and the Mini-Mental Status Examination. To assess the serum levels of brain-derived neurotrophic factor was used, the ELISA Kit, Promega Emax. Statistical analysis of data was performed using the ANOVA test and the Pearson’s correlation coefficient with a significance level.
Results: The groups of patients with Alzheimer´s disease without depression and Alzheimer´s disease with depression, showed significant differences in the Mini-Mental Status Examination performance, but not regarding the serum brain-derived neurotrophic factor levels. The higher correlation was observed in the Alzheimer´s disease with depression group, between the serum brain-derived neurotrophic factor and the cognitive function.
Conclusions: Depression in Alzheimer´s disease increase cognitive impairment and they positively correlate with the serum brain-derived neurotrophic factor. This factor is suggested as potential biomarker of cognitive impairment in Alzheimer´s disease with depression and it could be involved in the pathophysiology of this comorbidity.


REFERENCES

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed Washington DC: American Psychiatric Association; 2013. Disponible en: http://repository.poltekkeskaltim.ac.id/657/1/pdf

  2. World Health Organization, et al. Risk reduction of cognitive decline and dementia: WHO guidelines; 2019. Geneva: World Health Organization.

  3. World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2017. DOI: 10.2471/BLT.20.251405

  4. Ana VR, Estela GA, Juan LlR, Pastor CF, Rodolfo BB, Tania ZLl. Percepción de las demencias y la intersectorialidad en el contexto del Policlínico Docente Playa. Rev Cubana Salud Pública. 2019 [acceso: 16/1/2021]; 45(1):1128. Dispoible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-34662019000100011&lng=pt

  5. Bartels C, Wagner M, Wolfsgruber S, Ehrenreich H & Schneider A. Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer's dementia in individuals with previous depression. Am J Psychiatry. 2018;175(3):232-241. DOI: 10.1176/appi.ajp.2017.17040404

  6. Ismail Z, Elbayoumi H, Fischer CE, Hogan DB, Millikin, CP, Schweizer T, et al. Prevalence of depression in patients with mild cognitive impairment: a systematic review and meta-analysis. JAMA psychiatry. 2017;74(1):58-67. DOI: jamapsychiatry.2016.3162

  7. Lara B, Carnes A, Dakterzada F, Benitez I, & Piñol-Ripoll G. Neuropsychiatric symptoms and quality of life in spanish patients with Alzheimer’s disease during the COVID-19 lockdown. Eur J Neurol. 2020;27(9):1744-7. DOI: 10.1111/ene.14339

  8. Sapolsky RM, Krey LC, & McEwe BS. The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Science of Aging Knowledge Environment. Endocr Rev. 1986;7:284-301. PMID: 3527687

  9. Ennis GE, An Y, Resnick SM, Ferrucci L, O'Brien RJ, & Moffat SD. Long-term cortisol measures predict Alzheimer disease risk. Neurology. 2017;88(4):371–8. DOI: 10.1212/WNL.0000000000003537

  10. Kim NG, Lauren MB, Benno R, James LM & Frank ML. Glucocorticoids increase amyloid-β and tau pathology in a mouse model of Alzheimer’s disease.Journal of Neuroscience. 2006; 26(35):9047-56; DOI: 10.1523/JNEUROSCI.2797-06.2006

  11. Yang T, Nie Z, Shu H, Kuang Y, Chen X, Cheng J, et al. The role of BDNF on neural plasticity in depression. Frontiers in cellular neuroscience. 2020; 14:82. DOI: 10.3389/fncel.2020.00082

  12. Kowiański P, Lietzau G, Czuba E, Waskow M, Steliga A and Morys J. BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity. Cell Mol Neurobiol. 2018;38:579–593. DOI: 10.1007/s10571-017-0510-4

  13. Sierksma AS, van den Hove DL, Steinbusch HW, & Prickaerts J. Major depression, cognitive dysfunction and Alzheimer's disease: is there a link? European Journal of Pharmacology. 2010;626(1):72-82. 10.1016/j.ejphar.2009.10.021 14. Amidfar M, de Oliveira J, Kucharska E, Budni J, Kim YK. The role of CREB and BDNF in neurobiology and treatment of Alzheimer's disease. Life Sci. 2020;257:118020. DOI: 10.1016/j.lfs.2020.118020

  14. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Budd Haeberlein S et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia. 2018;14(4):535-62. Disponible en: 10.1016/j.jalz.2018.02.018

  15. Dubois B. The Emergence of a New Conceptual Framework for Alzheimer’s Disease. Journal of Alzheimer's Disease. 2018;62(3):1059-66. DOI: 10.3233/JAD-170536

  16. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-4. DOI: 10.1212/wnl.43.11.2412-a

  17. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey MB, et al. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res. 1983;17(1):37-49. DOI: 10.1016/0022-3956(82)90033-4

  18. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res. 1975;12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6

  19. Anastasia A, Deinhardt K, Chao MV, Will N, Irmady K, Lee FS, et al. Val66Met polymorphism of BDNF alters prodomain structure to induce neuronal growth cone retraction. Nature communications. 2013;4(1):1-13. DOI: 10.1038/ncomms3490

  20. Declaración de Helsinki de la Asociación Médica Mundial. Principios éticos para las investigaciones médicas en seres humanos. Asamblea General, Fortaleza, Brasil. 2013;64.

  21. Chi S, Wang C, Jiang T, Zhu XC, Yu JT, & Tan L. The prevalence of depression in Alzheimer’s disease: a systematic review and meta-analysis. Current Alzheimer Research. 2015;12(2):189-98. DOI: 10.2174/1567205012666150204124310

  22. Dafsari FS, Jessen F. Depression an underrecognized target for prevention of dementia in Alzheimer’s disease. Transl Psychiatry. 2020;10:160. DOI: 10.1038/s41398-020-0839-1

  23. Da Silva R, Charles Ysaacc F, Paula AC, & Frausto VM. La depresión y su influencia en los cambios neuropsicológicos del adulto mayor con trastorno neurocognitivo leve debido a la enfermedad de Alzheimer. CES Psicología. 2019;12(1):69-79. DOI: 10.21615/cesp.12.1.6

  24. Pláteníka J, Buchala R, Jirák R, Kitzlerová E, Zvěřová M, říRaboch J. GSK3β, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2014;50:83-93. DOI: 10.1016/j.pnpbp.2013.12.001

  25. Tarvainen A, Hartikainen S, Taipale H, Tanskanen A, Koponen M, & Tolppanen AM. Association of recent hospitalisation with antidepressant initiation among community dwellers with Alzheimer's disease. International Journal of Geriatric Psychiatry. 2021;36(7):1075-84. DOI: 10.1002/gps.5505 27. Balietti M, Giuli C, Conti F. Peripheral Blood Brain-Derived Neurotrophic Factor as a Biomarker of Alzheimer's Disease: Are There Methodological Biases? Mol Neurobiol. 2018;55(8):6661-72. DOI: 10.1007/s12035-017-0866-y

  26. Shen XN, Niu LD, Wang YJ, Cao XP, Liu Q, Tan L, Zhang C, Yu JT. Inflammatory markers in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry. 2019;90(5):590-8. DOI: 10.1136/jnnp-2018-319148

  27. Zainab M, Rosliza, Behroz N, Ilyas MN, Nordin BS, Zubaidi ALA, et al. Synergistic Molecular Effect of BDNF, ApoE and MTHFR in inducing Depression in Alzheimer’s Disease. Research J. Pharm. and Tech. 2018;11(10): 4317-23.

  28. Mori Y, Tsuji M, Oguchi T, Kasuga K, Kimura A, Futamura A, et al. Serum BDNF as a Potential Biomarker of Alzheimer's Disease: Verification Through Assessment of Serum, Cerebrospinal Fluid, and Medial Temporal Lobe Atrophy. Front Neurol. 2021;12:653267. DOI: 10.3389/fneur.2021.653267




2020     |     www.medigraphic.com